- Home
- ZNTL vs VNDA Comparison
ZNTL vs VNDA Comparison
Compare ZNTL & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- VNDA
- Stock Information
- Founded
- ZNTL 2014
- VNDA 2002
- Country
- ZNTL United States
- VNDA United States
- Employees
- ZNTL N/A
- VNDA N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- VNDA Health Care
- Exchange
- ZNTL Nasdaq
- VNDA Nasdaq
- Market Cap
- ZNTL 105.8M
- VNDA 286.4M
- IPO Year
- ZNTL 2020
- VNDA 2006
- Fundamental
- Price
- ZNTL $1.39
- VNDA $4.77
- Analyst Decision
- ZNTL Buy
- VNDA Strong Buy
- Analyst Count
- ZNTL 7
- VNDA 3
- Target Price
- ZNTL $8.60
- VNDA $15.33
- AVG Volume (30 Days)
- ZNTL 1.4M
- VNDA 453.6K
- Earning Date
- ZNTL 08-08-2025
- VNDA 07-30-2025
- Dividend Yield
- ZNTL N/A
- VNDA N/A
- EPS Growth
- ZNTL N/A
- VNDA N/A
- EPS
- ZNTL N/A
- VNDA N/A
- Revenue
- ZNTL $26,865,000.00
- VNDA $201,351,000.00
- Revenue This Year
- ZNTL N/A
- VNDA $16.86
- Revenue Next Year
- ZNTL N/A
- VNDA $39.78
- P/E Ratio
- ZNTL N/A
- VNDA N/A
- Revenue Growth
- ZNTL N/A
- VNDA 13.37
- 52 Week Low
- ZNTL $1.01
- VNDA $3.81
- 52 Week High
- ZNTL $5.44
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- ZNTL 55.06
- VNDA 52.73
- Support Level
- ZNTL $1.29
- VNDA $4.67
- Resistance Level
- ZNTL $1.43
- VNDA $5.04
- Average True Range (ATR)
- ZNTL 0.10
- VNDA 0.20
- MACD
- ZNTL 0.02
- VNDA -0.01
- Stochastic Oscillator
- ZNTL 86.96
- VNDA 43.10
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.